Quick Takeaways: Why It Matters? CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoi...
Quick Takeaways: Why It Matters? Dechra has launched Laverdia (verdinexor tablets), the first and only FDA‑approved oral treatment for dogs with lymphoma, enabling at‑home therapy that can start on Day 1 after diagnosis. Canine lymphoma is one of the most common cancers i...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
